SCHEMBL64024

SCHEMBL64024

COC(=O)c1ccc(C(=O)O)cn1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.79
KDM4E B2RXH2 2/20 0.74
L3MBTL1 Q9Y468 1/20 0.74
P4HTM Q9NXG6 6/20 0.66
P4HA1 P13674 2/20 0.66
MIF P14174 1/20 0.66
HCAR3 P49019 5/20 0.53
MAPT P10636 1/20 0.50
GABRP O00591 1/20 0.48
GABRD O14764 1/20 0.48
GABRA1 P14867 1/20 0.48
GABRB1 P18505 1/20 0.48
GABRG2 P18507 1/20 0.48
GABRB3 P28472 1/20 0.48
GABRA5 P31644 1/20 0.48
GABRA3 P34903 1/20 0.48
GABRA2 P47869 1/20 0.48
GABRB2 P47870 1/20 0.48
GABRA4 P48169 1/20 0.48
GABRE P78334 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29826109 1.00 MAPK1 (0.79) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL69747 0.89 MAPK1 (1.00) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL29508473 0.89 MAPK1 (1.00) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL28630848 0.87 MAPK1 (0.60) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL64700 0.85 MAPK1 (1.00) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL989398 0.85 MAPK1 (0.79) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL21173949 0.85 P4HTM (0.70) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL8251331 0.84 MAPK1 (0.77) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL1019173 0.84 MAPK1 (0.77) MAPK1KDM4EL3MBTL1P4HTMP4HA1
SCHEMBL30401004 0.84 MAPK1 (0.77) MAPK1KDM4EL3MBTL1P4HTMP4HA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148752-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM BIOME BIOPLASTICS LIMITED (GB) 2018-05-31 US claimed
EP-3307901-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM Biome Bioplastics Limited (GB) 2018-04-18 EP claimed
CN-104363887-B Compositions, methods and uses comprising pyridine dicarboxylic acid esters and esters of glucose and fatty acids 莱雅公司 2017-11-10 CN claimed
CN-107106452-A Specific pyridinedicarboxylicacid acid derivatives/antioxidant combination 欧莱雅 2017-08-29 CN claimed
WO-2016202875-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM BIOME BIOPLASTICS LIMITED (GB) 2016-12-22 WO claimed
US-20050171346-A1 Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation AVENTIS PHARMA S.A. (FR) 2005-08-04 US claimed
US-20260085336-A1 NEW POLYMERS AND METHODS BIOME BIOPLASTICS LTD (GB) 2026-03-26 US disclosed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 EP disclosed
EP-4658667-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY Merck Sharp & Dohme LLC (US) 2025-12-10 EP disclosed
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use CARMOT THERAPEUTICS INC. (US) 2025-11-04 US disclosed
US-12454710-B2 Process for the preparation of 2,4- or 2,5-pyridinedicarboxylic acid and copolymers derived therefrom BIOME BIOPLASTICS LIMITED (GB) 2025-10-28 US disclosed
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-08-28 US disclosed
US-20250270475-A1 FABRIC AND HOME CARE COMPOSITION COMPRISING SURFACTANT AND A POLYESTER THE PROCTER & GAMBLE COMPANY 2025-08-28 US disclosed
CN-1076691-A Sulfonamido-and sulfonamidocarbonyl-pyridine-2-carboxamides and their pyridine-N-oxides HOECHST AG (DE) 1993-09-29 CN disclosed
EP-0267794-B1 PROCESS FOR PREPARING POLYOLEFINS Nippon Petrochemicals Co., Ltd. (JP) 1993-05-05 EP disclosed
US-4904675-A Phamacologically active 5-carboxy-2-(5-tetrazolyl) pyridines ZYMA SA (CH) 1990-02-27 US disclosed
EP-0278908-A2 Heterocyclic compounds Zyma SA (CH) 1988-08-17 EP disclosed
EP-0267794-A2 Process for preparing polyolefins Nippon Petrochemicals Co., Ltd. (JP) 1988-05-18 EP disclosed
US-4525555-A TITANIUM COMPOUND SUPPORTED ON SOLID REACTION PRODUCT OF MAGNESIUM HALIDE, SILOXANES, ORGANIC COMPOUNDS NIPPON OIL COMPANY, LIMITED (JP) 1985-06-25 US disclosed
US-4273779-A Treating hypertension with substituted-5-amino-2-pyridinecarboxylic acids CIBA-GEIGY CORPORATION (US) 1981-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS SMURF2, SMURF1, MDM2 MAPK1 4334/4885KDM4E 1052/4885L3MBTL1 1396/4885
US-12459929-B2 GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use GLP1R, GCGR, GIPR MAPK1 1342/4885KDM4E 3526/4885L3MBTL1 4709/4885
US-12454710-B2 Process for the preparation of 2,4- or 2,5-pyridinedicarboxylic acid and copolymers derived therefrom HPD, PCCA, MVD MAPK1 2904/4885KDM4E 657/4885L3MBTL1 4344/4885
US-20260085336-A1 NEW POLYMERS AND METHODS PGD, HPD, UROD MAPK1 4122/4885KDM4E 286/4885L3MBTL1 4524/4885
US-20050171346-A1 Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation HEXD, CDK5, CHUK MAPK1 88/4885KDM4E 2612/4885L3MBTL1 4847/4885
US-20180148752-A1 PROCESS FOR THE PREPARATION OF 2,4- OR 2,5-PYRIDINEDICARBOXYLIC ACID AND COPOLYMERS DERIVED THEREFROM HPD, PCCA, MVD MAPK1 2904/4885KDM4E 657/4885L3MBTL1 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.